What Has Been the Growth Trajectory for the Scleroderma Market in Recent Years?
The scleroderma market has seen considerable growth due to a variety of factors.
•There has been robust growth in the scleroderma market size over recent years. Expected to increase from $2.33 billion in 2024 to $2.49 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 6.9%.
The historic period growth can be credited to improvements in diagnosis, immunological research, therapeutic developments, heightened awareness and education, as well as advances in genetic studies.
How Does the Forecast Look for the Scleroderma Market?
The scleroderma market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the scleroderma market is anticipated to experience significant growth, with an estimated value of $3.25 billion by 2029 and a compound annual growth rate (CAGR) of 6.9%.
The anticipated growth during the forecast period is likely due to advancements in biological therapies, precision medicine, stem cell therapies, genomic and biomarker studies, and global collaborations. The period will also witness certain key trends like the adoption of digital health solutions, emphasis on microbiome, patient-centered care, regenerative medicine, and a focus on health equity and access.
What Are the Critical Driver Fuelling the Scleroderma Market's Growth?
The escalating frequency of scleroderma is propelling the advance of the scleroderma market. Scleroderma, a long-standing autoimmune disease marked by the irregular proliferation of collagen, a vital component of skin and other tissue structures, is driven by an unrestrained immune reaction likely instigated by a range of environmental influences. With increasing instances of the disease, the necessity for enhanced recognition and medical intervention becomes clear. Scleroderma treatments play a pivotal role in disease management and symptom relief, manipulating the immune reactions and mitigating the effects of environmental hazards. For instance, as per Karger Publishers, a Swiss firm that publishes peer-reviewed journals, in June 2022, there were 19,000 scleroderma patients in the UK and 2.5 million internationally. Moreover, in August 2024, Oxford Academic Press, a university press associated with the University of Oxford in the UK, published a research article that identified 1,588 cases of systemic sclerosis (SSc) out of 10.1 million people in the CPRD, leading to 206 cancer diagnoses, predominantly mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Consequently, the scleroderma market is being propelled by the increasing frequency of scleroderma.
How Is the Scleroderma Market segmented?
The scleroderma market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End Users
Subsegments:
1) By Medication: Immunosuppressants, Antifibrotic Agents, Vasodilators, Corticosteroids, Pain Relievers
2) By Surgery: Lung Transplantation, Other Surgical Interventions
3) By Other Treatments: Physical Therapy, Occupational Therapy, Lifestyle Modifications, Alternative Therapies
Pre-Book The Scleroderma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Scleroderma Market?
One of the emerging trends in the scleroderma market is the rollout of innovative treatment options. To maintain their market standing, leading firms in this market are creating new medicines for handling scleroderma symptoms. As an example, Tyr Pharma Inc., a leading biotherapeutics producer in the USA, secured approval for its groundbreaking drug, efzofitimod, related to systemic sclerosis-linked interstitial lung disease from the US Food and Drug Administration in April 2022. This unprecedented immunomodulator uses modulation of the neuropilin-2 (NRP2) receptor to regulate the immune response, subsequently decreasing the symptoms of scleroderma. Moreover, Efzofitimod also works on the exact immune cells that cause SSc-ILD (interstitial lung disease in relation to systemic sclerosis) and pulmonary sarcoidosis, resulting in diminished pro-inflammatory markers, as observed in a clinical trial involving patients with pulmonary sarcoidosis.
Who Are the Key Players in the Scleroderma Market?
Major companies operating in the scleroderma market include:
• Pfizer Inc.
• Johnson And Johnson Inc.
• F. Hoffmann-La Roche AG
• Abbvie Inc.
• Bayer AG
• Novartis AG
• Merck And Co. Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Aspen Pharmacare Holdings Limited
• Boehringer Ingelheim International GmbH
• Principia Biopharma Corp
• aTyr Pharma Inc.
• Cumberland Pharmaceuticals Inc.
• Kadmon Holdings Inc.
• Emerald Health Pharmaceuticals Inc.
• FibroGen Inc.
• Argentis Pharmaceuticals LLC
• Corbus Pharmaceuticals Holdings Inc.
• H.A.C. Pharma
What Is The Most Dominant Region In The Scleroderma Market?
North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
